1 - 13 of 13
Dr. Schultz's research involves using magnetic resonance imaging to understand brain mechanisms and to create biomarkers that predict who has autism spectrum disorder (ASD), who will develop the disorder, and who will respond well to different interventions. More recently, he has developed a technology and innovation lab to exploit advances in perceptual computing, in order to develop more robust measurements of quantitative traits.
Relies on extensive experience in leadership positions in institution, independent, and governmental Institutional Review Boards to support investigators while they navigate multicenter research studies.
Dr. Shah's research is centered on understanding obesity and its related complications. Her current work includes clinical and translational studies exploring pathophysiology and modulation of obesity-related adipose tissue and systemic inflammation using human cell lines and clinical trials. She is also involved in clinical studies of outcomes and risk factors of polycystic ovarian syndrome and type 2 diabetes in teens.
Dr. Silverman studies the fundamental aspects of early-life commensal microbes that influence immune system development and function. He discovered that the MHC-II E molecule prevents type 1 diabetes by shaping the intestinal microbiota early in life.
Dr. Spinner's research focuses on the etiology and expressivity of pediatric developmental disorders. She uses genomic methods to focus on the multisystem disorder Alagille syndrome and biliary atresia, a likely heterogeneous and poorly understood condition. She is also interested in using genomic tools to continue to improve diagnostic rates for constitutional genetic disorders.
Dr. Stallings is working on intervention trials involving three chronic diseases with nutrition-related abnormalities resulting in meaningful adverse outcomes: cystic fibrosis (new drugs), sickle cell disease (vitamin A) and chronic pancreatitis (enzyme replacement drug).
Dr. Steenhoff is medical director of the Global Health Center at Children's Hospital. He serves as a global health advocate for children, seeking to optimize mutually beneficial partnerships between clinical and academic institutions in diverse settings.
Dr. Sullivan's research focuses on new and rare immunodeficiencies. She has a long-standing interest in one of the most common of the primary immunodeficiencies – chromosome 22q11.2 deletion syndrome. She also investigates common variable immunodeficiency, as well as the genetics and epigenetics of systemic lupus erythematosus.
Promoting collaboration between academia and industry by developing relationships with other institutions, biotechnology, pharmaceutical, and medical device companies to continue research and to commercialize CHOP research discoveries and technology-based ventures.